Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Hematology"
DOI: 10.1007/s12185-018-2422-6
Abstract: Kinase domain (KD) mutations of ABL1 represent the most common resistance mechanism to tyrosine kinase inhibitors (TKI) in CML. Besides T315I, mutations in codon 255 are highly resistant mutations in vitro to all TKI. We… read more here.
Keywords: kinase domain; patients e255k; response; domain mutations ... See more keywords